7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Cachexia D002100 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
HIV Infections D015658 20 associated lipids
Wounds and Injuries D014947 20 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Carcinoma D002277 18 associated lipids
Albuminuria D000419 18 associated lipids
Brain Infarction D020520 17 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
García-Hernández A et al. High glucose concentrations alter the biomineralization process in human osteoblastic cells. 2012 Bone pmid:22086137
Chao TH et al. Opposite associations of osteoprotegerin and ZBTB40 polymorphisms with bone mineral density of the hip in postmenopausal Taiwanese women. 2012 J Chin Med Assoc pmid:22824048
Terpos E et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. 2011 Nov-Dec Clin. Exp. Rheumatol. pmid:22032557
Arikan F et al. C-telopeptide pyridinoline crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with peri-implantitis: a case-control study. 2011 Mar-Apr Int J Oral Maxillofac Implants pmid:21483881
Crespi R et al. Corticocancellous porcine bone in the healing of human extraction sockets: combining histomorphometry with osteoblast gene expression profiles in vivo. 2011 Jul-Aug Int J Oral Maxillofac Implants pmid:21841997
Franke S et al. Advanced glycation end products affect growth and function of osteoblasts. 2011 Jul-Aug Clin. Exp. Rheumatol. pmid:21906430
Rezg R et al. Inhibitors of vascular calcification as potential therapeutic targets. 2011 Jul-Aug J. Nephrol. pmid:21688249
Reyes-García R et al. [Cardiovascular disease and bone metabolism]. 2011 Aug-Sep Endocrinol Nutr pmid:21775224
Wang Y et al. LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells. 2011 Mol. Cell. Endocrinol. pmid:21291955
Szulc P et al. Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study. 2011 J. Clin. Endocrinol. Metab. pmid:21565793
Zhang M et al. EP1(-/-) mice have enhanced osteoblast differentiation and accelerated fracture repair. 2011 J. Bone Miner. Res. pmid:20939055
Millard SM et al. Blockade of receptor-activated G(i) signaling in osteoblasts in vivo leads to site-specific increases in cortical and cancellous bone formation. 2011 J. Bone Miner. Res. pmid:20939063
Zhang Y et al. Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone. 2011 PLoS ONE pmid:21897843
Tanaka H et al. Expression of RANKL/OPG during bone remodeling in vivo. 2011 Biochem. Biophys. Res. Commun. pmid:21771583
Meulman T et al. Impact of Porphyromonas gingivalis inoculation on ligature-induced alveolar bone loss. A pilot study in rats. 2011 J. Periodont. Res. pmid:21726226
Yang L et al. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation. 2011 Chin. Med. J. pmid:22088466
Reinhard H et al. Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. 2011 Cardiovasc Diabetol pmid:21801376
Gordon IK and Camphausen K Research highlights. 2011 Biomark Med pmid:21861664
Jabbar S et al. Plasma vitamin D and cytokines in periodontal disease and postmenopausal osteoporosis. 2011 J. Periodont. Res. pmid:20731767
Lossdörfer S et al. PTH(1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells. 2011 Clin Oral Investig pmid:20697756
Yang XY et al. [Influence of surface modification of titanium on OPG/RANKL mRNA expression in MG-63 human osteoblast-like cells]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:21868322
Malliga DE et al. The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review. 2011 Wien Med Wochenschr pmid:21870142
Guo HL et al. [Experimental study on the mechanism of icariin improving human osteoblasts proliferation and the expression of OPG protein]. 2011 Zhongguo Gu Shang pmid:21870401
McGrath EE OPG/RANKL/RANK pathway as a therapeutic target in cancer. 2011 J Thorac Oncol pmid:21849854
Findlay DM and Atkins GJ Relationship between serum RANKL and RANKL in bone. 2011 Osteoporos Int pmid:21850548
Harada S and Takahashi N [Control of bone resorption by RANKL-RANK system]. 2011 Clin Calcium pmid:21814016
Nakamura M and Udagawa N [Osteoporosis and RANKL signal]. 2011 Clin Calcium pmid:21814019
Persson E and Lerner UH The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. 2011 J. Cell. Biochem. pmid:21815197
Üstündağ M et al. The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. 2011 J. Int. Med. Res. pmid:21819709
Christoforidis A et al. Comparative study of dual energy X-ray absorptiometry and quantitative ultrasonography with the use of biochemical markers of bone turnover in boys with haemophilia. 2011 Haemophilia pmid:20825502
Shin M et al. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. 2011 Carcinogenesis pmid:21890459
Grigoropoulou P et al. The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease. 2011 Curr. Med. Chem. pmid:21919846
Riancho JA and Delgado-Calle J [Osteoblast-osteoclast interaction mechanisms]. 2011 Reumatol Clin pmid:21924211
Peng S et al. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. 2011 Bone pmid:21925296
Fan R et al. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin expression in chronic apical periodontitis: possible association with inflammatory cells. 2011 Chin. Med. J. pmid:21933620
Osorio A et al. Mineral-bone metabolism markers in young hemodialysis patients. 2011 Clin. Biochem. pmid:21933667
Nybo M et al. Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. 2011 Basic Clin. Pharmacol. Toxicol. pmid:21726411
Fradet A et al. Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. 2011 Cancer Res. pmid:21734015
Ashley DT et al. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. 2011 Metab. Clin. Exp. pmid:21087777
Campbell GM et al. Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. 2011 Osteoporos Int pmid:20480144
Tekkesin MS et al. The role of RANK/RANKL/OPG signalling pathways in osteoclastogenesis in odontogenic keratocysts, radicular cysts, and ameloblastomas. 2011 Head Neck Pathol pmid:21643971
Jiang JQ et al. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder. 2011 Nephrology (Carlton) pmid:21649792
Choi EM Honokiol isolated from Magnolia officinalis stimulates osteoblast function and inhibits the release of bone-resorbing mediators. 2011 Int. Immunopharmacol. pmid:21621646
Ueland T et al. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. 2011 J. Intern. Med. pmid:21623962
Wheater G et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. 2011 Osteoporos Int pmid:21625887
Karadag-Saygi E et al. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis. 2011 Gynecol. Endocrinol. pmid:21627558
Taylor R et al. Osteoclast formation and function in pigmented villonodular synovitis. 2011 J. Pathol. pmid:21706481
Conaway HH et al. Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor. 2011 J. Biol. Chem. pmid:21715325
El-Shehaby A et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. 2011 J. Clin. Immunol. pmid:21691937
Roshandel D et al. Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men. 2011 Calcif. Tissue Int. pmid:21964949
Davenport C et al. Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk. 2011 J. Hypertens. pmid:21970938
Kanayama K et al. Osteoclast and osteoblast activities on carbonate apatite plates in cell cultures. 2011 J Biomater Appl pmid:20624844
Ikeda K et al. Conditional expression of constitutively active estrogen receptor α in osteoblasts increases bone mineral density in mice. 2011 FEBS Lett. pmid:21439958
Teramachi J et al. Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis. 2011 Lab. Invest. pmid:21339747
Katz J et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. 2011 Int J Oral Maxillofac Surg pmid:21396799
Cianciolo G et al. Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. 2011 Nephrol. Dial. Transplant. pmid:20659908
Bitto A et al. Genistein aglycone effect on bone loss is not enhanced by supplemental calcium and vitamin D3: a dose ranging experimental study. 2011 Phytomedicine pmid:21397481
Di Bartolo BA et al. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. 2011 Cardiovasc. Res. pmid:21447702
Ho TY et al. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. 2011 Bone pmid:21419242
Chasseraud M et al. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. 2011 Ther Apher Dial pmid:21426505
Duheron V et al. Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21402940
Dimitrow PP et al. The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. 2011 J. Heart Valve Dis. pmid:21404893
Marques EA et al. Effects of resistance and aerobic exercise on physical function, bone mineral density, OPG and RANKL in older women. 2011 Exp. Gerontol. pmid:21316442
Dimitriadis K et al. Exercise blood pressure response is related to asymmetric dimethylarginine and osteoprotegerin in hypertension. 2011 Int. J. Cardiol. pmid:21975354
Yao Y et al. Synergistic enhancement of new bone formation by recombinant human bone morphogenetic protein-2 and osteoprotegerin in trans-sutural distraction osteogenesis: a pilot study in dogs. 2011 J. Oral Maxillofac. Surg. pmid:22018252
Brown TT et al. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. 2011 Antivir. Ther. (Lond.) pmid:22024522
Mainini G et al. Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women. 2011 Clin Exp Obstet Gynecol pmid:22268274
Yener S et al. Is there an association between non-functioning adrenal adenoma and endothelial dysfunction? 2011 J. Endocrinol. Invest. pmid:20530985
Claro T et al. Staphylococcus aureus protein A binds to osteoblasts and triggers signals that weaken bone in osteomyelitis. 2011 PLoS ONE pmid:21525984
Giro G et al. Influence of estrogen deficiency on bone around osseointegrated dental implants: an experimental study in the rat jaw model. 2011 J. Oral Maxillofac. Surg. pmid:21530046
Won KY et al. RANK signalling in bone lesions with osteoclast-like giant cells. 2011 Pathology pmid:21532526
Naot D et al. Molecular mechanisms involved in the mitogenic effect of lactoferrin in osteoblasts. 2011 Bone pmid:21515435
Aydin H et al. Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats. 2011 Minerva Endocrinol. pmid:21519319
Altinova AE et al. Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. 2011 Scand. J. Clin. Lab. Invest. pmid:21486111
Mercatali L et al. Bone metastases detection by circulating biomarkers: OPG and RANK-L. 2011 Int. J. Oncol. pmid:21491082
Stein SH et al. Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts. 2011 J. Periodont. Res. pmid:21463327
Liang QQ et al. The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice. 2011 Bone pmid:21466864
Honda K Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes. 2011 J Oral Sci pmid:21467819
Dimitri P et al. Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. 2011 Bone pmid:20932948
Yu H et al. Overexpression of osteoprotegerin promotes preosteoblast differentiation to mature osteoblasts. 2011 Angle Orthod pmid:20936961
Palaniswamy C et al. Association of warfarin use with valvular and vascular calcification: a review. 2011 Clin Cardiol pmid:21298649
Sipos W et al. OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers. 2011 Horm. Metab. Res. pmid:22161252
Akinci B et al. Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome. 2011 Diabetes Res. Clin. Pract. pmid:20970873
Toffoli B et al. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. 2011 Mol. Cell. Endocrinol. pmid:20832449
Tang T et al. Effect of water-soluble P-chitosan and S-chitosan on human primary osteoblasts and giant cell tumor of bone stromal cells. 2011 Biomed Mater pmid:21205994
Attia EA et al. Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. 2011 Int. J. Dermatol. pmid:21182499
Sun Z and Tee BC Molecular variations related to the regional differences in periosteal growth at the mandibular ramus. 2011 Anat Rec (Hoboken) pmid:21157918
Cannon JG et al. Follicle-stimulating hormone promotes RANK expression on human monocytes. 2011 Cytokine pmid:21159522
Choe JY et al. Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin. 2011 J. Rheumatol. pmid:21159831
Mahoney DJ et al. TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. 2011 Arthritis Rheum. pmid:21162099
Čolović M et al. FGF-R3 and OPG expression in patient with multiple myeloma following systemic sclerosis: case report and review of the literature. 2011 Int. J. Hematol. pmid:21207214
Hashiguchi D et al. Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts. 2011 J Biomed Mater Res A pmid:21171155
Eslami B et al. Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. 2011 Calcif. Tissue Int. pmid:21327765
Jørgensen L et al. Serum osteoprotegerin levels are related to height loss: the Tromsø Study. 2011 Eur. J. Epidemiol. pmid:21331661
Yuan H et al. Receptor activator of nuclear factor kappa B ligand antagonists inhibit tissue inflammation and bone loss in experimental periodontitis. 2011 J. Clin. Periodontol. pmid:22092474
Garcia VG et al. Treatment of experimental periodontal disease with antimicrobial photodynamic therapy in nicotine-modified rats. 2011 J. Clin. Periodontol. pmid:22092666
Santini D et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. 2011 PLoS ONE pmid:21559440
Hen K et al. [Osteoprotegerin--a new atherosclerosis marker]. 2011 Pol. Merkur. Lekarski pmid:22097184
Mariúba MV et al. Effect of triiodothyronine on the maxilla and masseter muscles of the rat stomatognathic system. 2011 Braz. J. Med. Biol. Res. pmid:21584440
Tang Y et al. Porphyromonas endodontalis lipopolysaccharides induce RANKL by mouse osteoblast in a way different from that of Escherichia coli lipopolysaccharide. 2011 J Endod pmid:22099899

Table of Content